Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
18 hedge funds and large institutions have $8.65M invested in Biolase, Inc. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
31% less funds holding
Funds holding: 26 → 18 (-8)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
43% less capital invested
Capital invested by funds: $15.1M → $8.65M (-$6.44M)
80% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Princeton Capital Management
Red Bank,
New Jersey
|
+$37.7K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$18.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$15.1K |
| 4 |
BlackRock
New York
|
+$3.77K |
| 5 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$3.77K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
-$185K |
| 2 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$152K |
| 3 |
TA
Teton Advisors
Rye,
New York
|
-$94.2K |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
-$38K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16K |
BIOL Hedge Fund Activity: Q2 2018 in Review
18 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2018, worth a combined $8.65M — down 43% from $15.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of BIOL and 2 opened new positions — a net loss of 8 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Princeton Capital Management, adding an estimated $37.7K. The largest seller was Birchview Capital, cutting an estimated $185K.
- 18 institutional investors held Biolase, Inc. (BIOL) as of Q2 2018, down from 26 in Q1 2018.
- Funds reported $8.65M of Biolase, Inc. stock for Q2 2018, down 43% quarter-over-quarter.
- 2 funds opened new Biolase, Inc. positions in Q2 2018 and 10 closed out, a net change of -8 holders.
- The largest Biolase, Inc. buyer in Q2 2018 was Princeton Capital Management, an estimated $37.7K added.
- The largest Biolase, Inc. seller in Q2 2018 was Birchview Capital, an estimated $185K sold.
Based on aggregated 13F filings for Q2 2018.